CWEB1d
Genmab A/S (NASDAQ:GMAB) Sees Positive Analyst Attention and Share Transactions Disclosure
GMAB, is a biotechnology company known for its innovative antibody therapeutics. Established in 1999 and based in Copenhagen, ...
William Blair Comments on Genmab A/S FY2029 Earnings
Equities research analysts at William Blair issued their FY2029 earnings per share (EPS) estimates for shares of Genmab A/S ...
William Blair Increases Earnings Estimates for Genmab A/S
William Blair upped their FY2028 EPS estimates for Genmab A/S in a research note issued on Monday, March 10th. William Blair ...
Fintel on MSN4d
William Blair Upgrades Genmab A (GMAB)
Fintel reports that on March 11, 2025, William Blair upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform ...
Genmab sinks as J&J opts not to develop Darzalex successor; stock upgraded
Genmab (CSE:GMAB) (NASDAQ:GMAB) announced on Monday, March 10, that Johnson&Johnson (NYSE:JNJ) has chosen not to proceed with the development of GEN3014 (HexaBody-CD38), a next-gen version of their ...
William Blair upgrades Genmab with focus now on pipeline
William Blair analyst Matthew Phipps last night upgraded Genmab (GMAB) to Outperform from Market Perform without a price target. after the ...
Positive Report for Genmab (GMAB) from William Blair
Genmab (GMAB – Research Report) received a Buy rating and price target from William Blair analyst Matt Phipps today. The company’s shares ...
Fierce Biotech5d
J&J opts out of licensing Genmab's Darzalex challenger after look at phase 1/2 data
Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...
Fierce Biotech5d
Beam gene therapy for protein deficiency passes early safety test, sets efficacy bar in space: analyst
The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), ...
manilatimes15d
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody ...
Yahoo Finance15d
Is William Blair Small-Mid Cap Growth R6 (WSMRX) the Worst Performing Mutual Fund in 2024?
In this article, we are going to take a look at where William Blair Small-Mid Cap Growth R6 (WSMRX) stands against other worst performing mutual funds in 2024. Mutual funds with exposure to large ...